MedPath

Serial IGRA screening for lung cancer patients receiving immune checkpoint inhibitors

Not Applicable
Conditions
non-small cell lung cancer patients who receiving immune checkpoint inhibitors
Registration Number
JPRN-UMIN000036533
Lead Sponsor
ational Hospital Organization Kyoto Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

none

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
positive conversion rate of IGRA at a year after induction of immune checkpoint inhibitor therapy
Secondary Outcome Measures
NameTimeMethod
incidence of active TB at a year after induction of immune checkpoint inhibitor therapy
© Copyright 2025. All Rights Reserved by MedPath